Fig. 6
From: Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis
Anti-fibrotic effects of raloxifene in the bleomycin-induced model of systemic sclerosis. a Their dorsal skin thickness was examined by histology, Scale bars, 100 μm. b Quantification of the skin thickness by histology of the bleomycin induction model. c-e Expression of the fibrosis marker genes of COL1A1, COL3A1 and ACTA2 in bleomycin model. f, g After 3 weeks of raloxifene treatment, bleomycin mice skin expression of pSMAD was assessed by western blot analysis. All graphs show the mean and standard error of the mean (*p < 0.05, **p < 0.01, ***p < 0.001, as determined by Student’s t test)